Roundtable Discussion: Advancing Preclinical Models to Better Predict Clinical Outcomes in Chronic Lung Disease
- Where do traditional animal and smoke models fall short in replicating human COPD features such as exacerbations, airway remodeling, and complex inflammatory networks?
- How can preclinical models be improved to better reflect human disease biology through approaches such as smoke exposure models, molecular biomarkers, and advanced imaging?
- To what extent should human data and mechanistic insights take precedence over preclinical models in candidate selection?
- How can the field better align preclinical findings with clinical endpoints to reduce late-stage failure in respiratory drug development?
- What role should emerging technologies such as organoids, lung-on-chip systems, and AI play in enhancing translational predictability?